Advertisement

Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke

      The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register. The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003 and 2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel. Clopidogrel and aspirin plus dipyridamole were compared to aspirin. A direct comparison between clopidogrel and aspirin plus dipyridamole was also performed. Outcomes included all-cause mortality and a combined end point of all-cause mortality and incidence of major adverse cardiac events (stroke or myocardial infarction). Cox-regression models adjusted for potential confounders at the following time periods after discharge; 0 to 90 days, 91 to 365 days, and 1 to 3 years. Aspirin plus dipyridamole was associated with a lower risk of mortality at 0 to 90 days; hazard ratio (HR) 0.62 (0.43 to 0.91). Clopidogrel was associated with a lower risk of mortality at 1 to 3 years; HR of 0.39 (0.26 to 0.60). Similar HRs were observed for the corresponding time points in the composite outcome. In conclusion, patients with noncardioembolic stroke may gain maximum benefits from aspirin plus dipyridamole initially (≤1 year) with a subsequent switch to clopidogrel, with regard to mortality and major adverse cardiac eventsoutcomes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Verro P
        • Gorelick PB
        • Nguyen D
        Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
        Stroke. 2008; 39: 1358-1363
        • CAPRIE Steering Committee
        A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Sacco RL
        • Diener HC
        • Yusuf S
        • Cotton D
        • Ounpuu S
        • Lawton WA
        Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
        N Engl J Med. 2008; 359: 1238-1251
        • National Institute for Health and Care Excellence (NICE)
        Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events.
        NICE, London2014
      1. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. [published online May 1, 2014]. Stroke doi:10.1161/STR.000000000000000024.

        • European Stroke Organization (ESO)
        Guidelines for management of ischaemic stroke and transient ischaemic attack.
        Cerebrovasc Dis. 2008; 25: 457-507
        • Bettencourt-Silva J
        • De La Iglesia B
        • Donnel S
        • Rayward-Smith V
        On creating a patient-centric database from multiple hospital information systems.
        Methods Inf Med. 2012; 51: 210-220
        • Lee M
        • Wu Y
        • Saver J
        • Lee HC
        • Lee JD
        • Chang KC
        • Wu CY
        • Lee TH
        • Wang HH
        • Rao NM
        • Ovbiagele B
        Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
        BMJ Open. 2014; 4e006672https://doi.org/10.1136/bmjopen-2014-006672
        • McQuaid KR
        • Laine L
        Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.
        Am J Med. 2006; 119: 624-638
        • Caneschi S
        • Bonaventi C
        • Finzi F
        Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22–34 months).
        Minerva Med. 1985; 76: 1933-1943
        • Guiraud-Chaumeil B
        • Rascol A
        • David J
        • Boneu B
        • Clanet M
        • Bierme R
        Pre´vention des re´cidives des accidents vasculaires ce´re´braux ische´miques par les anti-agre´gants plaquettaires: resultants d'un essai the´rapique controle´ de 3 ans.
        Rev Neurol. 1982; 138: 367-385
        • Bousser MG
        • Eschwege E
        • Haguenau M
        • Lefaucconnier JM
        • Thibult N
        • Touboul D
        • Touboul PJ
        “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia.
        Stroke. 1983; 14: 5-14
        • American-Canadian Cooperative Study Group
        Persantine aspirin trial in cerebral ischemia, part II: endpoint results.
        Stroke. 1985; 16: 406-415
        • Diener H-C
        • Cunha L
        • Forbes C
        • Sivenius J
        • Smets P
        • Lowenthal A
        European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
        J Neurol Sci. 1996; 143: 1-13
        • Halkes PH
        • Van Gijn J
        • Kappelle LJ
        • Koudstaal PJ
        • Algra A
        Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
        Lancet. 2006; 367: 1665-1673
        • Verro P
        • Gorelick P
        • Nguyen D
        Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA.
        Stroke. 2008; 39: 1358-1363
        • Diener HC
        • Sacco RL
        • Yusuf S
        • Cotton D
        • Ounpuu S
        • Lawton WA
        • Palesch Y
        • Martin RH
        • Albers GW
        • Bath P
        • Bornstein N
        • Chan BP
        • Chen ST
        • Cunha L
        • Dahlof B
        • De Keyser J
        • Donnan GA
        • Estol C
        • Gorelick P
        • Gu V
        • Hermansson K
        • Hilbrich L
        • Kaste M
        • Lu C
        • Machnig T
        • Pais P
        • Roberts R
        • Skvortsova V
        • Teal P
        • Toni D
        • VanderMaelen C
        • Voigt T
        • Weber M
        • Yoon BW
        Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischemic stroke in the Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS) trial: a double-blind, active and placebo-controlled study.
        Lancet Neurol. 2008; 7: 875-884
        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • Casey Jr, DE
        • Ganiats TG
        • Holmes Jr, DR
        • Jaffe AS
        • Jneid H
        • Kelly RF
        • Konton MC
        • Levine GN
        • Liebson PR
        • Mukherjee D
        • Peterson E
        • Sabatine MS
        • Smalling RW
        • Zieman SJ
        2014 AHA.ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines.
        J Am Coll Cardiol. 2014; 64: e139-e228
        • Johnston SC
        • Amarenco P
        • Albers GW
        • Denison H
        • Easton JD
        • Evans SR
        • Held P
        • Jonasson J
        • Minematsu K
        • Molina CA
        • Wang Y
        • Wong KS
        • SOCRATES Steering Committee and Investigators
        Ticagrelor versus aspirin in acute stroke or transient ischemic attack.
        N Engl J Med. 2016; 7: 35-43
        • Liu Y
        • Fei Z
        • Wang W
        • Fang J
        • Meijuan Z
        • Cheng G
        Efficacy and safety of short-term dual- versus mono-antiplatelet therapy in patients with ischemic stroke or TIA: a meta-analysis of 10 randomized controlled trials.
        J Neurol. 2016; 263: 2247-2259
        • Wilson SJ
        • Newby D
        • Dawson D
        • Irving J
        • Berry C
        Duration of dual antiplatelet therapy in acute coronary syndrome.
        Heart. 2017; 103: 573-580
        • Kwok CS
        • Clark A
        • Ford GA
        • Durairaj R
        • Dixit AK
        • Davis J
        • Sharma AK
        • Potter JF
        • Myint PK
        Association between prestrike disability and inpatient mortality and length of acute hospital stay after acute stroke.
        J Am Geriatr Soc. 2012; 60: 726-732
        • Bamford J
        • Sandercock P
        • Dennis M
        • Warlow C
        • Burn J
        Classification and natural history of clinically identifiable subtypes of cerebral infarction.
        The Lancet. 1991; 337: 1521-1526
        • Sinha S
        • Myint PK
        • Luben RN
        • Khaw KT
        Accuracy of death certification and hospital record linkage for identification of incident stroke.
        BMC Med Res Methodol. 2008; 8: 74